Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
VBI Vaccines
Pharma
Takeda, WuXi, LianBio—Fierce Pharma Asia
Takeda finally won an FDA nod for Eohilia. U.S. lawmakers want sanctions against WuXi for national security reasons. LianBio will shut down. Plus more.
Angus Liu
Feb 16, 2024 8:24am
VBI Vaccines shrinks 'long-term burn' with $33M Brii Bio deal
Feb 14, 2024 11:12am
AZ-Daiichi, Moderna, Takeda and more—Fierce Pharma Asia
Jul 7, 2023 9:45am
EMA expands nods for BMS, Eli Lilly, Novartis drugs
Feb 25, 2022 11:42am
FDA approves VBI's PreHevbrio just as HBV market is set to grow
Dec 1, 2021 10:34am
Heplisav-B; Janssen and more—News of Note
Feb 27, 2019 9:14am
